Your browser doesn't support javascript.
loading
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-ß.
Yam, Clinton; Murthy, Rashmi K; Rauch, Gaiane M; Murray, James L; Walters, Ronald S; Valero, Vicente; Brewster, Abenaa M; Bast, Robert C; Booser, Daniel J; Giordano, Sharon H; Esteva, Francisco J; Yang, Wei; Hortobagyi, Gabriel N; Moulder, Stacy L; Arun, Banu.
Affiliation
  • Yam C; Department of Breast Medical Oncology, Dan L. Duncan Building (CPB5.3542), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.
  • Murthy RK; Department of Breast Medical Oncology, Dan L. Duncan Building (CPB5.3542), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.
  • Rauch GM; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Murray JL; Department of Breast Medical Oncology, Dan L. Duncan Building (CPB5.3542), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.
  • Walters RS; Department of Breast Medical Oncology, Dan L. Duncan Building (CPB5.3542), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.
  • Valero V; Department of Breast Medical Oncology, Dan L. Duncan Building (CPB5.3542), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.
  • Brewster AM; Department of Breast Medical Oncology, Dan L. Duncan Building (CPB5.3542), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.
  • Bast RC; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Booser DJ; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Giordano SH; Department of Breast Medical Oncology, Dan L. Duncan Building (CPB5.3542), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.
  • Esteva FJ; Department of Breast Medical Oncology, Dan L. Duncan Building (CPB5.3542), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.
  • Yang W; Department of Breast Medical Oncology, Dan L. Duncan Building (CPB5.3542), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.
  • Hortobagyi GN; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Moulder SL; Department of Breast Medical Oncology, Dan L. Duncan Building (CPB5.3542), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.
  • Arun B; Department of Breast Medical Oncology, Dan L. Duncan Building (CPB5.3542), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.
Invest New Drugs ; 36(6): 1103-1109, 2018 12.
Article in En | MEDLINE | ID: mdl-30311036
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 3_ND Database: MEDLINE Main subject: Breast Neoplasms / Proto-Oncogene Proteins c-kit / Receptor, Platelet-Derived Growth Factor beta / Imatinib Mesylate / Letrozole Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Invest New Drugs Year: 2018 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 3_ND Database: MEDLINE Main subject: Breast Neoplasms / Proto-Oncogene Proteins c-kit / Receptor, Platelet-Derived Growth Factor beta / Imatinib Mesylate / Letrozole Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Invest New Drugs Year: 2018 Document type: Article